Baltimore, MD, United States of America

Feyruz Rassool


 

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2015-2019

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Feyruz Rassool: Innovator in Cancer Treatment

Introduction

Feyruz Rassool is a prominent inventor based in Baltimore, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. With a total of 5 patents, Rassool's work focuses on enhancing the effectiveness of cancer therapies.

Latest Patents

Rassool's latest patents include groundbreaking methods for treating cancer cells. One of his notable inventions is a therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in multiple cancers. This patent outlines methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Additionally, he has developed similar methods specifically targeting ovarian cancer, providing new avenues for treatment.

Career Highlights

Throughout his career, Rassool has worked with esteemed institutions such as the University System of Maryland and The Johns Hopkins University. His research has been pivotal in advancing cancer treatment methodologies, showcasing his dedication to improving patient outcomes.

Collaborations

Rassool has collaborated with notable professionals in his field, including Stephen B Baylin and Carine Robert. These partnerships have further enriched his research and contributed to the development of innovative cancer therapies.

Conclusion

Feyruz Rassool's contributions to cancer treatment through his patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to inspire advancements in cancer therapies, making a significant impact on patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…